Chimeric antigen receptor T (CAR-T) cells have made brilliant achievements in the treatment of many kinds of malignant tumors, and six kinds of CAR-T products have been approved by the Food and Drug Administration (FDA), bringing new hope for the treatment of diseases. However, the complications associated with CAR-T cell therapy should not be ignored. Neurological complications often jeopardize patients’ lives, including immune effector cell-associated neurotoxicity syndrome, cerebrovascular accidents, movement and neurocognitive treatment-emergent adverse events. The current knowledge of the mechanism and treatment of these complications is still insufficient, which is a direction that needs to be solved in the future.
JainMDSmithMShahNN.How I treat refractory CRS and ICANS following CAR T-cell therapy. Blood2023;
141: 2430–2442.
2.
GrantSJGrimshawAASilbersteinJ, et al.
Clinical presentation, risk factors, and outcomes of immune effector Cell-Associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transplant Cell Ther2022;
28: 294–302.
3.
KarschniaPMillerKCYeeAJ, et al.
Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood2023;
142: 1243–1248.
4.
StratiPNastoupilLJWestinJ, et al.
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv2020;
4: 3943–3951.
5.
SchusterSJBishopMRTamCS, JULIET Investigatorset al.
Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med2019;
380: 45–56.
6.
NeelapuSSJacobsonCAGhobadiA, et al.
5-Year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1). Blood. Published Online February2023;
141: 2307–2315.
7.
WangMMunozJGoyA, et al.
KTE-X19 CAR T-cell therapy in relapsed or refractory Mantle-cell lymphoma. N Engl J Med2020;
382: 1331–1342.
8.
AbramsonJSPalombaMLGordonLI, et al.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet2020;
396: 839–852.
9.
MunshiNCAndersonLDShahN, et al.
Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med2021;
384: 705–716.
10.
BerdejaJGMadduriDUsmaniSZ, et al.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet2021;
398: 314–324.
11.
LeeDWSantomassoBDLockeFL, et al.
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant2019;
25: 625–638.
12.
SantomassoBDParkJHSalloumD, et al.
Clinical and biologic correlates of neurotoxicity associated with CAR T cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL). Cancer Discov2018;
8: 958–971.
13.
SalesCAndersonMAKuznetsovaV, et al.
Patterns of neurotoxicity among patients receiving chimeric antigen receptor T‐cell therapy: a single‐centre cohort study. Eur J Neurol2024;
31: e16174.
14.
GattoLRicciottiITosoniA, et al.
CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap. Front Oncol2023;
13: 1206983.
15.
Gonzalez CastroLNDietrichJ.Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. Neurooncol Pract2021;
8: 259–265.
16.
CohenADParekhSSantomassoBD, et al.
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J2022;
12: 32.
17.
YorichikaYNeshigeSEdahiroT, et al.
An early neurological indicator of immune effector Cell-Associated neurotoxicity syndrome. Cureus2024;
16: e57298.
18.
GustJPonceRLilesWC, et al.
Cytokines in CAR T cell–associated neurotoxicity. Front Immunol2020;
11: 577027.
19.
GustJHayKAHanafiLA, et al.
Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov2017;
7: 1404–1419.
20.
ElmarasiMElkonaissiIElsabaghAA, et al.
CAR-T cell therapy: efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up. Int Immunopharmacol2024;
135: 112312.
21.
CohenADGarfallALStadtmauerEA, et al.
B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma. J Clin Invest2019;
129: 2210–2221.
22.
ShalabiHMartinSYatesB, et al.
Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies. Neuro Oncol2022;
24: 1584–1597.
23.
DiorioCShraimRMyersR, et al.
Comprehensive serum proteome profiling of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome patients with B-Cell ALL receiving CAR T19. Clin Cancer Res2022;
28: 3804–3813.
24.
Castaneda-PuglianiniOChavezJC.Assessing and management of neurotoxicity after CAR-T therapy in diffuse large B-cell lymphoma. J Blood Med2021;
12: 775–783.
25.
SweeneyMDZhaoZMontagneA, et al.
Blood-brain barrier: from physiology to disease and back. Physiol Rev2019;
99: 21–78.
26.
ParkerKRMiglioriniDPerkeyE, et al.
Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell2020;
183: 126–142.e17.
27.
SalekiKMohamadiMHAlijanizadehP, et al.
Neurological adverse effects of chimeric antigen receptor T-cell therapy. Expert Rev Clin Immunol2023;
19: 1361–1383.
28.
VinnakotaJMBiavascoFSchwabenlandM, et al.
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat Cancer2024; Aug
5: 1227–1249.
29.
NieEHAhmadianSSBharadwajSN, et al.
Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma. J Neuropathol Exp Neurol2023;
82: 160–168.
30.
FontanelliLPizzanelliCMilanoC, et al.
Pre-existing frontal lobe dysfunction signs as predictors of subsequent neurotoxicity in CAR T cell therapy: insights from a case series. Neurol Sci2023;
44: 3291–3297.
31.
LemoineJVicSHouotR.Disease-specific outcomes after chimeric antigen receptor T-cell therapy. Eur J Cancer2022; Jan
160: 235–242.
32.
JacobsonCAChavezJCSehgalAR, et al.
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol2022;
23: 91–103.
33.
CappellKMKochenderferJN.A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat Rev Clin Oncol2021;
18: 715–727.
34.
MuchaSRRajendramP.Management and prevention of cellular-therapy-related toxicity: early and late complications. Curr Oncol2023;
30: 5003–5023.
35.
MazinaniM.CAR-T cell potency: from structural elements to vector backbone components. Biomarker Res2022;
10: 70.
36.
De MatteisSDicataldoMCasadeiB, et al.
Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity. Front Immunol2022;
13: 1058126.
37.
LeahyABNewmanHLiY, et al.
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol2021;
8: e711–e722.
38.
VelascoRMussettiAVillagrán-GarcíaM, et al.
CAR T-cell-associated neurotoxicity in Central nervous system hematologic disease: is it still a concern?Front Neurol2023;
14: 1144414.
39.
SowellHGatwoodKPerciavalleM.Incidence and severity of ICANS following CAR-T therapy in patients previously receiving ifosfamide. Bone Marrow Transplant2023;
58: 219–221.
40.
Yakoub-AghaIChabannonCBaderP, et al.
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the european society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE). Haematologica2020;
105: 297–316.
41.
JohnsonPCNeckermannISadrzadehH, et al.
Clinical outcomes and toxicity in older adults receiving chimeric antigen receptor T cell therapy. Transplant Cell Ther2024;
30: 490–499.
42.
MaugetMLemercierSQuelvenQ, et al.
Impact of diagnostic investigations in the management of CAR T-cell–associated neurotoxicity. Blood Adv2024;
8: 2491–2498.
43.
HubySGelissePTudesqJJ, et al.
Frontal intermittent rhythmic Delta activity is a useful diagnostic tool of neurotoxicity after CAR T-Cell infusion. Neurol Neuroimmunol Neuroinflamm2023;
10: e200111.
44.
SatyanarayanSSpiegelJHovsepianD, et al.
Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy. Neurohospitalist2023;
13: 53–60.
45.
MorbelliSGambellaMRaiolaAM, et al.
Brain FDG‐PET findings in chimeric antigen receptor T‐cell therapy neurotoxicity for diffuse large B‐cell lymphoma. J Neuroimaging2023;
33: 825–836.
46.
SchoeberlFTiedtSSchmittA, et al.
Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment. Blood Adv2022;
6: 3022–3026.
47.
KorellFPenackOMattieM, et al.
EASIX and severe endothelial complications after CD19-directed CAR-T cell therapy – a cohort study. Front Immunol2022;
13: 877477.
48.
ZhaoYZhangXZhangM, et al.
Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy. Ann Hematol2024;
103: 969–980.
49.
AmidiYEckhardtCAQuadriSA, et al.
Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy. J ImmunoTher Cancer2022;
10: e005459.
50.
JonesDKEckhardtCASunH, et al.
EEG-based grading of immune effector cell-associated neurotoxicity syndrome. Sci Rep2022;
12: 20011.
51.
KhalidFGuptaRGorR, et al.
Neurological adverse effects of immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. World J Oncol2023;
14: 109–118.
52.
AlsalemANScarffeLABriembergHR, et al.
Neurologic complications of cancer immunotherapy. Curr Oncol2023;
30: 5876–5897.
53.
GaffneyKJDavisJAMcGannM, et al.
Early versus standard management of chimeric antigen receptor therapy toxicities and management’s impact on safety and efficacy. J Oncol Pharm Pract2024;
30: 151–158.
54.
PensatoUPondrelliFDe PhilippisC, et al.
Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy. Neurol Sci2024;
45: 4107.
55.
PensatoUMuccioliLZinzaniP, et al.
Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review. J Neurol2022;
269: 4560–4563.
56.
PensatoUAmoreGMuccioliL, et al.
CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and assessment in lymphoma (CARBON–NEUTRAL): proposed protocol and results from an italian study. J Neurol2023;
270: 2659–2673.]
57.
BhojwaniDBansalRWayneAS.Managing therapy-associated neurotoxicity in children with ALL. Hematology Am Soc Hematol Educ Program2021;
2021: 376–383.
58.
CostaBAFlynnJNishimuraN, et al.
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J2024;
14: 84.
59.
ShalabiHHarrisonCYatesB, et al.
Intrathecal hydrocortisone for treatment of children and young adults with CAR T‐cell immune‐effector cell‐associated neurotoxicity syndrome. Pediatr Blood Cancer2024;
71: e30741.
60.
WangXQiYLiH, et al.
Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy. Front Immunol2022;
13: 943004.
61.
KatsinMShmanTMigasA, et al.
Case report: rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone. Front Immunol2024;
15: 1380451.
62.
AsawaPVusqaUKhanC, et al.
Intrathecal chemotherapy as a potential treatment for steroid-refractory immune effector cell-associated neurotoxicity syndrome. Anticancer Res2022;
42: 3853–3856.
63.
GiavridisTVan Der StegenSJCEyquemJ, et al.
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med2018;
24: 731–738.
64.
WehrliMGallagherKChenYB, et al.
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J ImmunoTher Cancer2022;
10: e003847.
65.
GazeauNLiangECWuQV, et al.
Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplant Cell Ther2023;
29: 430–437.
66.
ParkJHNathKDevlinSM, et al.
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med2023;
29: 1710–1717.
67.
SternerRMSakemuraRCoxMJ, et al.
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood2019;
133: 697–709.
68.
GongNHanXXueL, et al.
In situ PEGylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity. Nat Mater2023;
22: 1571–1580.
69.
BajwaAZhaoQGeerM, et al.
Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis. Blood Adv2025;
9: 170–175.
70.
HaydenPJRoddieCBaderP, et al.
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol2022;
33: 259–275.
71.
WangLXia YuXQiu CaoJ, et al.
Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient. Int J Hematol2021;
114: 408–412.
72.
LemoineJBachyECartronG, et al.
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv2023;
7: 6589–6598.
73.
KerstenMJVan EttekovenCNHeijinkDM.Unexpected neurologic complications following a novel lymphoma treatment ‘expected’ to give rise to neurologic toxicity. BMJ Case Rep2019;
12: e229946.
74.
MaugetMLemercierSHouotR, et al.
Immune effector cell-associated acute stroke: a novel entity?Eur J Cancer2023;
194: 113352.
75.
RubinDBDanishHHAliAB, et al.
Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain2019;
142: 1334–1348.
76.
CordeiroABezerraEDHirayamaAV, et al.
Late events after treatment with CD19-Targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant2020;
26: 26–33.
77.
LefebvreBKangYVakilpourA, et al.
Incidence of MACE in patients treated with CAR-T cell therapy. Jacc Cardiooncol2023;
5: 747–754.
78.
YanZCaoJChengH, et al.
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol2019;
6: e521–e529.
79.
GuoGGuoWFengY, et al.
Therapeutic time window of minimally invasive surgery for intracerebral hemorrhage. Brain Hemorrhages2020;
1: 158–160.
80.
Van OekelenOAlemanAUpadhyayaB, et al.
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med2021;
27: 2099–2103.
81.
MartinTUsmaniSZBerdejaJG, et al.
Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol2023;
41: 1265–1274.
82.
TostHHWeissNChoquetS, et al.
Neurotoxicity in patients with CNS lymphomas treated with CAR‐T cell therapy. A LOC network study. Hematol Oncol2023;
41: 536–537.
83.
MailankodySDevlinSMLandaJ, et al.
GPRC5D-Targeted CAR T cells for myeloma. N Engl J Med2022;
387: 1196–1206.
84.
SdrimasKDiaz-PaezMCamargoJF, et al.
Progressive multifocal leukoencephalopathy after CAR T therapy. Int J Hematol2020;
112: 118–121.
85.
CousinEBelicardFMichelL, et al.
Severe cytomegalovirus disease with encephalitis after CAR‐T cell therapy: a rare but potentially fatal complication. J Med Virol2021;
93: 6398–6403.
86.
PeggsKS.Human herpesvirus 6 and CAR T-cell toxicity. Blood2024;
144: 465–466.
87.
KampouriEKrantzEMXieH, et al.
Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients. Blood2024;
144: 490–495.
88.
LiNZhangRWangJ, et al.
Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma. Front Neurol2024;
15: 1334000.
89.
BrudnoJNKochenderferJN.Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol2024;
21: 501–521.
90.
AnJZhaoJZouP, et al.
Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: risks and prevention strategies. Cancer Med2024;
13: e7372.
91.
MajznerRGRamakrishnaSYeomKW, et al.
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature2022;
603: 934–941.
92.
MahdiJDietrichJStraathofK, et al.
Tumor inflammation-associated neurotoxicity. Nat Med2023;
29: 803–810.
93.
StaykovDSchwabS.Posterior reversible encephalopathy syndrome. J Intensive Care Med2012;
27: 11–24.
94.
GarfallALLancasterEStadtmauerEA, et al.
Posterior reversible encephalopathy syndrome (PRES) after infusion of anti-bcma CAR T cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide. Blood2016;
128: 5702–5702.
95.
DiorioCHernandez-MiyaresLEspinozaDA, et al.
Quadriparesis and paraparesis following chimeric antigen receptor T-cell (CART) therapy in children and adolescents. Blood2024;
144: 1387–1398.
96.
Deschênes-SimardXSantomassoBDDahiPB.Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy. Blood2024;
144: 2083–2094.
97.
KubokiMUmezawaYMotomuraY, et al.
Severe motor weakness due to disturbance in peripheral nerves following tisagenlecleucel treatment. In Vivo2021;
35: 3407–3411.
